Prospective Assessment of Rejection in Kidney Transplant (PARK)

Description

The PARK study is a multi-center observational study to assess the performance of the QSant test with kidney biopsy. QSant is a test based on 6 urinary biomarkers that is used for the evaluation and management of acute rejection in renal allograft recipients with clinical suspicion of rejection.

Conditions

Kidney Transplant Failure and Rejection

Study Overview

Study Details

Study overview

The PARK study is a multi-center observational study to assess the performance of the QSant test with kidney biopsy. QSant is a test based on 6 urinary biomarkers that is used for the evaluation and management of acute rejection in renal allograft recipients with clinical suspicion of rejection.

Prospective Assessment of Rejection in Kidney Transplant (PARK)

Prospective Assessment of Rejection in Kidney Transplant (PARK)

Condition
Kidney Transplant Failure and Rejection
Intervention / Treatment

-

Contacts and Locations

Murray

Intermountain Medical Center, Murray, Utah, United States, 84107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Kidney transplant recipient ≥ 18 years who are scheduled for kidney biopsy.
  • 2. Kidney biopsy scheduled on a date \> 14 days post-transplant
  • 3. Able to understand risks and requirements of participation and provide informed consent
  • 4. Willing and able to comply with the study requirements
  • 1. Inability to provide a voided urine sample per collection protocol
  • 2. Urological abnormalities such as catheters, augmented bladder, ileal conduits, mitrofanoff, and vesicostomy
  • 3. History of or current multi-organ transplant

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NephroSant,

Study Record Dates

2023-09-30